Treatments for Epilepsy and Sympto… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

Kimberly Nye

Tax Period

2023-01-01 to 2023-12-31

Treatments for Epilepsy and Symptoms of, founded in 2015, is a small nonprofit in the Medical Research sector that reported $504K in total revenue in fiscal year 2023. Revenue decreased 18% compared to the prior year.

Mission

Tess Research Foundations goal is to find better treatment options for SLC13A5 deficiency, (Continued on Sch O)

Program Service Accomplishments

Program 1

Expenses: $302,455

Funding Scientific Research - We continued our in-person, digital and remote natural history studies for SLC13A5 with Ciitizen Corporation, Brown University, UT Southwestern, and Stanford University. These studies are key for our clinical trial readiness. We also funded basic and translational research.

Program 2

Expenses: $117,833

Education, Family Support and Awareness - We are the only organization dedicated to supporting families with SLC13A5 Epilepsy and raising awareness about the disease. Our ongoing program includes...

Education, Family Support and Awareness - We are the only organization dedicated to supporting families with SLC13A5 Epilepsy and raising awareness about the disease. Our ongoing program includes sharing updates about the latest research findings and connecting and empowering families so they can share their experiences and support one another. We have an annual awareness day (May 13), host monthly virtual support calls, maintain a website, and send a monthly electronic newsletter.

Program 3

Expenses: $8,772

Conference - We continue to create a patient-centered network of doctors, researchers, clinicians, and families. We attend neurology, epilepsy, and drug development conferences and host research...

Conference - We continue to create a patient-centered network of doctors, researchers, clinicians, and families. We attend neurology, epilepsy, and drug development conferences and host research roundtables to build partnerships and share current research.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $433,322

Program Service Revenue $0

Investment Income $0

Other Revenue $70,325

TOTAL REVENUE $503,647

Expense Breakdown

Grants Paid $152,845

Salaries & Benefits $277,164

Fundraising Expenses $48,269

Program Expenses $429,060

Other Expenses $67,678

TOTAL EXPENSES $497,687

Year-over-Year Comparison

	2023	2022	Change
Revenue	$503,647	$610,734	-0.2%
Expenses	$497,687	$868,351	-0.4%
Net Income	$5,960	$-257,617	-1.0%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
Adam Alberti	Director	2.00	Director	$0	$0	$0
Lee Scheuer	Director	3.00	Director	$0	$0	$0
Robert Wassman	Director	3.00	Director	$0	$0	$0
Courtney Alberti	Director	2.00	Director	$0	$0	$0
Kimberly Nye	Chair & Executive Director	40.00	Officer Director	$0	$0	$0
Michael Black	Vice Chair as of 51	5.00	Officer Director	$0	$0	$0
Paula Gani	Secretary	5.00	Officer Director	$0	$0	$0
Kevin McDonnell	Treasurer	3.00	Officer Director	$0	$0	$0
Amber Black	Vice Chair until 430	5.00	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$503,647	$497,687	$459,776	$5,960
2022	$610,734	$868,351	$447,207	$-257,617
2021	$381,268	$466,822	$717,894	$-85,554
2020	$675,901	$113,779	$798,282	$562,122
2019	$392,669	$368,510	$223,542	$24,159
2018	$286,889	$172,923	$198,894	$113,966

Treatments for Epilepsy and Symptoms of